ALTERITY THERAPEUTICS LIMITED - AMERICAN DEPOSITAR

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

12 Nov 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

06 Nov 2024 07:35:00 By Nasdaq GlobeNewswire

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

31 Oct 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

14 Oct 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

11 Oct 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

02 Oct 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

30 Sep 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

23 Sep 2024 07:35:00 By Nasdaq GlobeNewswire

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

31 Jul 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Present at MST Financial Webinar

24 Jul 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

17 Jul 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

17 Jul 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar

12 Jun 2024 19:22:16 By Nasdaq GlobeNewswire

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

29 May 2024 19:21:24 By Nasdaq GlobeNewswire

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

08 May 2024 07:25:00 By Nasdaq GlobeNewswire

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

30 Apr 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia

29 Apr 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

17 Apr 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

10 Apr 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

26 Mar 2024 10:25:00 By Nasdaq GlobeNewswire